(Q37630026)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

meta-analysis

0 references

title

Vasculopathy in patients with Fabry disease: current controversies and research directions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

S M Rombach

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Th B Twickler

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

G E Linthorst

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

F A Wijburg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C E M Hollak

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

13 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

99-108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19900828%20AND%20SRC:MED&resulttype=core&format=json

Enzymatic Defect in Fabry's Disease

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Fabry's Disease: Alpha-Galactosidase Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

The cerebral vasculopathy of Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Renal pathological changes in Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

The heart in Anderson Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Ultrastructural study of renal involvement in two females with Anderson-Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Intermittent claudication -- atypical presentation, diagnosis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Small bowel ischaemia in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Atypical Fabry's disease presenting with cholesterol crystal embolization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Coronary artery bypass grafting for Fabry's disease: veins more suitable than arteries?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Postmortem diagnosis of Fabry disease with acromegaly and a unique vasculopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Cellular and tissue localization of globotriaosylceramide in Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Diagnostic utility of different MRI and MR angiography measures in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Cerebrovascular complications of Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Intravascular ultrasound assessment of coronary artery involvement in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Images in cardiovascular medicine. Myocardial fibrosis in fabry disease demonstrated by multislice computed tomography: comparison with biopsy findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry's disease. Review of cardiovascular manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Vasospastic angina in a patient with Fabry's disease who showed normal coronary angiographic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Structural and functional changes in peripheral vasculature of Fabry patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Non-invasive evaluation of arterial involvement in patients affected with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Arterial wall properties and Womersley flow in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Peripheral hemodynamics in patients with Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Fabry disease in a heterozygote presenting as hand ischaemia and painful acroparaesthesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Enhanced endothelium-dependent vasodilation in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Selective arterial distribution of cerebral hyperperfusion in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Quantitative analysis of cerebral vasculopathy in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Stroke in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Microembolus Detection in Four Patients with Fabry’s Disease: Further Support for a Primarily Microangiopathic Origin of Early Cerebrovascular Symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Thrombosis in Japanese patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Central retinal artery occlusion in a patient with Fabry's disease documented by scanning laser ophthalmoscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Central Retinal Artery Occlusion Complicating Fabry's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

A case of anterior ischemic optic neuropathy associated with Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Retinal and choroidal vascular changes in heterozygous Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Ischemic optic neuropathy in a female carrier with Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Several functional and fluorescein fundus angiographic findings in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Endothelial nitric oxide synthase gene polymorphisms in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Relationship of eNOS gene variants to diseases that have in common an endothelial cell dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Natural history of Fabry disease in affected males and obligate carrier females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Failure to detect Fabry patients in a cohort of prematurely atherosclerotic males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Role of smooth muscle cells in the initiation and early progression of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

The effect of noradrenaline, angiotensin II and vasopressin on blood flow and sensitivity to heat in capsaicin-treated skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Decreased nitric oxide bioavailability in a mouse model of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004

Endothelial markers and homocysteine in patients with classic Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.004